1. Cell Cycle/DNA Damage
    Cytoskeleton
    Autophagy
  2. Microtubule/Tubulin
    Autophagy

Vinorelbine ditartrate (Synonyms: KW-2307; Nor-5'-anhydrovinblastine ditartrate)

Cat. No.: HY-12053A Purity: 99.62%
Handling Instructions

Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.

For research use only. We do not sell to patients.
Vinorelbine ditartrate Chemical Structure

Vinorelbine ditartrate Chemical Structure

CAS No. : 125317-39-7

Size Price Stock Quantity
10 mM * 1 mL in DMSO $71 In-stock
10 mg $60 In-stock
50 mg $180 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of Vinorelbine ditartrate:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.

In Vitro

Vinorelbine (0.5-5 nM) inhibits cell proliferation by 50% (IC50) at concentrations of 1.25 nM. At concentration of 8 nM vinorelbine, no cells are in anaphase[1]. Vinorelbine time-dependently induces the p53 and p21WAFI/CIP1 expression in androgen-dependent (AD) and- independent (AI) prostate cancer cell lines. Vinorelbine stimulates reporter genes in a concentration-dependent manner[2].

In Vivo

After vinorelbine treatment, the first neutropenicepisode occurred after the first (4 dogs), second (1), or sixth(1) vinorelbine treatment in the dogs[3]. Vinorelbine is tolerated at a weekly interval in tumor-bearing cats, with an MTD of 11.5 mg/m2[4].

Clinical Trial
Sponsor Condition Start Date Phase
Sun Yat-Sen University Esophagus tumor 2007-06-30 Phase 3
Heinrich Heine Universitat Dusseldorf Metastatic breast cancer 2012-02-29 Phase 3
National Hospital Organization Kinki-chuo Chest Medical Center Metastatic non small cell lung cancer 2004-04-30 Phase 3
Eisai Inc Metastatic non small cell lung cancer 2011-09-30 Phase 3
Merck & Co Inc Ovary tumor 2011-04-30 Phase 3
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 0.9267 mL 4.6334 mL 9.2669 mL
5 mM 0.1853 mL 0.9267 mL 1.8534 mL
10 mM 0.0927 mL 0.4633 mL 0.9267 mL
Animal Administration
[4]

Vinorelbine is diluted in 0.9% NaCl to a concentration of 1.5 mg/mL.

As defined by the study, VRL1 is diluted in 0.9% NaCl to a concentration of 1.5 mg/mL, and given IV over 5 minutes. The intended treatment interval is 7 days for up to 4 treatments. After receiving 4 weekly doses, cats are eligible to continue VRL treatment every 2 weeks.

References
M.Wt

1079.11

Formula

C₅₃H₆₆N₄O₂₀

CAS No.

125317-39-7

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 46 mg/mL

Purity: 99.62%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vinorelbine ditartrate
Cat. No.:
HY-12053A
Quantity: